Cargando…

ALOX5AP is a new prognostic indicator in acute myeloid leukemia

BACKGROUND: The overexpression of ALOX5AP has been observed in many types of cancer and has been identified as an oncogene. However, its role in acute myeloid leukemia (AML) has not been extensively studied. This study aimed to identify the expression and methylation patterns of ALOX5AP in bone marr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin-Yi, Wen, Xiang-Mei, Zhao, Wei, Chu, Ming-Qiang, Gu, Yu, Huang, Hai-Hui, Yuan, Qian, Xu, Zi-Jun, Qian, Jun, Lin, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667204/
https://www.ncbi.nlm.nih.gov/pubmed/37994961
http://dx.doi.org/10.1007/s12672-023-00826-9
_version_ 1785149017126076416
author Chen, Xin-Yi
Wen, Xiang-Mei
Zhao, Wei
Chu, Ming-Qiang
Gu, Yu
Huang, Hai-Hui
Yuan, Qian
Xu, Zi-Jun
Qian, Jun
Lin, Jiang
author_facet Chen, Xin-Yi
Wen, Xiang-Mei
Zhao, Wei
Chu, Ming-Qiang
Gu, Yu
Huang, Hai-Hui
Yuan, Qian
Xu, Zi-Jun
Qian, Jun
Lin, Jiang
author_sort Chen, Xin-Yi
collection PubMed
description BACKGROUND: The overexpression of ALOX5AP has been observed in many types of cancer and has been identified as an oncogene. However, its role in acute myeloid leukemia (AML) has not been extensively studied. This study aimed to identify the expression and methylation patterns of ALOX5AP in bone marrow (BM) samples of AML patients, and further explore its clinical significance. METHODS: Eighty-two de novo AML patients and 20 healthy donors were included in the study. Meanwhile, seven public datasets from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) were included to confirm the alteration of ALOX5AP. Receiver operating characteristic (ROC) curve analysis was applied to determine the discriminative capacity of ALOX5AP expression to discriminate AML. The prognostic value of ALOX5AP was identified by the Kaplan–Meier method and log-rank test. It was further validated in four independent cohorts (n = 1186). Significantly different genes associated with ALOX5AP expression were subsequently compared by LinkedOmics, and Metascape database. RESULTS: The level of ALOX5AP expression was significantly increased in bone marrow cells of AML patients compared with healthy donors (P < 0.05). ROC curve analysis suggested that ALOX5AP expression might be a potential biomarker to discriminate AML from controls. ALOX5AP overexpression was associated with decreased overall survival (OS) in AML according to the TCGA data (P = 0.006), which was validated by other four independent cohorts. DNA methylation levels of ALOX5AP were significantly lower in AML patients compared to normal samples (P < 0.05), as confirmed in the Diseasemeth database and the independent cohort GSE63409. ALOX5AP level was positively associated with genes with proleukemic effects such as PAX2, HOX family, SOX11, H19, and microRNAs that act as oncogenes in leukemia, such as miR125b, miR-93, miR-494, miR-193b, while anti-leukemia-related genes and tumor suppressor microRNAs such as miR-582, miR-9 family and miR-205 were negatively correlated. CONCLUSION: ALOX5AP overexpression, associated with its hypomethylation, predicts poorer prognosis in AML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00826-9.
format Online
Article
Text
id pubmed-10667204
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-106672042023-11-23 ALOX5AP is a new prognostic indicator in acute myeloid leukemia Chen, Xin-Yi Wen, Xiang-Mei Zhao, Wei Chu, Ming-Qiang Gu, Yu Huang, Hai-Hui Yuan, Qian Xu, Zi-Jun Qian, Jun Lin, Jiang Discov Oncol Research BACKGROUND: The overexpression of ALOX5AP has been observed in many types of cancer and has been identified as an oncogene. However, its role in acute myeloid leukemia (AML) has not been extensively studied. This study aimed to identify the expression and methylation patterns of ALOX5AP in bone marrow (BM) samples of AML patients, and further explore its clinical significance. METHODS: Eighty-two de novo AML patients and 20 healthy donors were included in the study. Meanwhile, seven public datasets from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) were included to confirm the alteration of ALOX5AP. Receiver operating characteristic (ROC) curve analysis was applied to determine the discriminative capacity of ALOX5AP expression to discriminate AML. The prognostic value of ALOX5AP was identified by the Kaplan–Meier method and log-rank test. It was further validated in four independent cohorts (n = 1186). Significantly different genes associated with ALOX5AP expression were subsequently compared by LinkedOmics, and Metascape database. RESULTS: The level of ALOX5AP expression was significantly increased in bone marrow cells of AML patients compared with healthy donors (P < 0.05). ROC curve analysis suggested that ALOX5AP expression might be a potential biomarker to discriminate AML from controls. ALOX5AP overexpression was associated with decreased overall survival (OS) in AML according to the TCGA data (P = 0.006), which was validated by other four independent cohorts. DNA methylation levels of ALOX5AP were significantly lower in AML patients compared to normal samples (P < 0.05), as confirmed in the Diseasemeth database and the independent cohort GSE63409. ALOX5AP level was positively associated with genes with proleukemic effects such as PAX2, HOX family, SOX11, H19, and microRNAs that act as oncogenes in leukemia, such as miR125b, miR-93, miR-494, miR-193b, while anti-leukemia-related genes and tumor suppressor microRNAs such as miR-582, miR-9 family and miR-205 were negatively correlated. CONCLUSION: ALOX5AP overexpression, associated with its hypomethylation, predicts poorer prognosis in AML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00826-9. Springer US 2023-11-23 /pmc/articles/PMC10667204/ /pubmed/37994961 http://dx.doi.org/10.1007/s12672-023-00826-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Chen, Xin-Yi
Wen, Xiang-Mei
Zhao, Wei
Chu, Ming-Qiang
Gu, Yu
Huang, Hai-Hui
Yuan, Qian
Xu, Zi-Jun
Qian, Jun
Lin, Jiang
ALOX5AP is a new prognostic indicator in acute myeloid leukemia
title ALOX5AP is a new prognostic indicator in acute myeloid leukemia
title_full ALOX5AP is a new prognostic indicator in acute myeloid leukemia
title_fullStr ALOX5AP is a new prognostic indicator in acute myeloid leukemia
title_full_unstemmed ALOX5AP is a new prognostic indicator in acute myeloid leukemia
title_short ALOX5AP is a new prognostic indicator in acute myeloid leukemia
title_sort alox5ap is a new prognostic indicator in acute myeloid leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667204/
https://www.ncbi.nlm.nih.gov/pubmed/37994961
http://dx.doi.org/10.1007/s12672-023-00826-9
work_keys_str_mv AT chenxinyi alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT wenxiangmei alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT zhaowei alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT chumingqiang alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT guyu alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT huanghaihui alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT yuanqian alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT xuzijun alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT qianjun alox5apisanewprognosticindicatorinacutemyeloidleukemia
AT linjiang alox5apisanewprognosticindicatorinacutemyeloidleukemia